Core Insights - The establishment of the global R&D center by Sanofi Bio in Hunan Xiangjiang New Area represents a significant investment of 500 million RMB and aims to enhance research and development in the biosensor industry, particularly in wearable and high-end implantable medical devices [1][5] - The company has successfully expanded its blood glucose meter products to 187 countries, becoming the fourth largest blood glucose meter manufacturer globally [1][9] - The chairman of the company, Li Shaobo, emphasizes the importance of aligning with future market demands and technological advancements for the company's evolution [1][4] Company Development - Sanofi Bio was founded in 2002 by Li Shaobo, who recognized the potential for diabetes management solutions in China, where the diabetes prevalence rate increased significantly from 0.7% in 1980 to 4.5% in urban areas by 2002 [3][4] - The company has benefited from favorable policies and a supportive entrepreneurial environment in Hunan Xiangjiang New Area, which has facilitated its growth and innovation [5][7] - Sanofi Bio has established long-term partnerships with local universities and hospitals, enhancing its research capabilities and technological advancements [5][9] International Expansion - In 2012, Sanofi Bio became the first publicly listed company in China's biosensor industry, marking a significant milestone in its internationalization strategy [8] - The company has pursued overseas acquisitions to enhance its global presence and operational efficiency, focusing on integrating financial, IT, HR, and management systems across its international operations [8][9] - The establishment of an international talent service center in Hunan Xiangjiang New Area has supported the recruitment of overseas talent, further strengthening the company's international capabilities [8][9] Adaptation to AI Era - In 2021, the company adjusted its vision to become a global leader in diabetes digital management, recognizing the need to embrace AI technology for future growth [10][11] - The company is implementing a digital transformation strategy to enhance customer interactions and operational efficiency through data-driven solutions [11][13] - Sanofi Bio's new product, the Continuous Glucose Monitoring System (CGM), reflects its commitment to integrating smart devices and big data technology for improved patient management [13] Future Outlook - The completion of the global R&D center is expected to position Sanofi Bio as a leader in diabetes management, leveraging cutting-edge technologies to drive innovation in the biomedicine sector [1][13] - The company aims to build a comprehensive diabetes management system that incorporates AI and digital technologies, contributing to the development of Hunan's biomedicine industry [13]